drugset
drugset / Trial / NCT06360419

Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol

NCT06360419 ↗

Phase 3 Completed 346 enrolled Axsome Therapeutics, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

PARADIGM (Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol) is a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial to assess the safety and efficacy of solriamfetol for the treatment of major depressive disorder (MDD) in adults.

Timeline

Start
2024-03-18
Primary completion
2024-12-31
Completion
2025-03-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Solriamfetol Small molecule 300 mg —

Indications

major depressive disorder